At a glance
- Originator AstraZeneca
- Class Antihypertensives
- Mechanism of Action Calcium channel antagonists; Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 06 Sep 2000 Discontinued-Preclinical for Hypertension in USA (Unknown route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 26 Aug 1997 No-Development-Reported for Hypertension in USA (Unknown route)